MMP-12及其抑制因子TIMP-1在基底细胞癌和鳞状细胞癌患者皮损中的表达

目的：明确基质金属蛋白酶-12(MMP-12)及其抑制因子-1（TIMP-1）与基底细胞癌（BCC）和鳞状细胞癌（SCC）的相关性。方法：通过免疫组化法检测MMP-12及TIMP-1在20例正常皮肤组织（NC）和31例基底细胞癌（BCC）、25例皮肤鳞状细胞癌患者（SCC）皮损中的表达。结果： MMP-12、TIMP-1在BCC和SCC中均呈弥漫性阳性表达。MMP-12在BCC和SCC患者中表达阳性率分别为45.2% 和80%,高于正常组的5%(P＜0.05),TIMP-1在BCC和SCC患者中表达阳性率分别为67.7%和60%,低于正常组的90%（P＜0.05）。结论：MMP-12、TIMP-1蛋白可能在BCC和SCC发病中发挥重要作用。     

皮肤基底细胞癌和皮肤鳞状细胞癌270例回顾性分析

 目的:总结我院皮肤基底细胞癌(BCC)和皮肤鳞状细胞癌(SCC)临床与组织病理资料,以期提高BCC与SCC的诊断率。方法：回顾性分析2014年1月1日-2018年12月31日间我院皮肤科门诊经组织病理切片确诊的170例BCC与100例SCC患者的临床与病理资料。结果：BCC与SCC年度发病整体均呈逐渐上升趋势。BCC、SCC男女患病比例分别为0.8∶1、1∶1，好发部位均为曝光部位(头面颈部和四肢)，临床诊断与组织病理诊断符合率分别为62.4%与30.0%。临床诊断上，BCC易与脂溢性角化病(SK)、色素痣混淆；SCC易与BCC、鲍温病、光线性角化病(AK)混淆。结论：BCC和SCC为临床常见的非黑素性皮肤肿瘤，但易误诊和漏诊。临床医生对于可疑病灶应尽早行皮损组织病理检查。     

钬激光联合光动力治疗头面部难治性基底细胞癌和鳞状细胞癌疗效评价

目的:评价钬激光联合光动力治疗19例基底细胞癌(BCC)及7例头面部鳞状细胞癌(SCC)的临床疗效。方法:首先采用钬激光对病变组织进行消融,再使用光动力进行联合治疗,随访12~18个月。结果:10例皮损完全消退(BCC8例、SCC2例);9例(BCC6例、SCC3例)皮损缩小≥50%;复发6例(BCC4例、SCC2例),总有效率73.08%。结论:钬激光联合光动力治疗头面部BCC和SCC有效。     

SGK1在日光性角化病、基底细胞癌及鳞状细胞癌中的表达

目的：检测SGK1在日光性角化病（AK）、基底细胞癌（BCC）及鳞状细胞癌（SCC）中的表达。方法：采用免疫组化SABC法检测SGK1在25例正常皮肤(NS)、25例AK、28例BCC、28例皮肤鳞状细胞癌标本中的表达。结果：NS、AK、BCC和SCC标本中,SGK1阳性细胞率分别为（40.03±14.42）%,（36.63±14.28）%,（52.82±18.73）%和（52.58±20.13）%。BCC组和SCC组分别与NS组比较,差异均有统计学意义（Ps<0.05）。各组SGK1染色阳性细胞率>50%的标本分别为6例（24%）,3例（12%）,16例（57.14%）和14例（50%）,BCC组和SCC组分别与NS组比较,差异均有统计学意义（Ps<0.05）。结论：SGK1的高表达可能与基底细胞癌及鳞状细胞癌的发病有关。     

基底细胞癌和鳞状细胞癌皮损中Smad2、Smad3和Smad4 mRNA表达下调

目的：检测转化生长因子β（TBF-β）/Smad信号转导途径中Smad2、Smad3和Smad4mRNA在基底细胞癌（BCC）和鳞状细胞癌（SCC）中的表达水平。方法：应用反转录一实时定量聚合酶链式反应（PCR）方法分别检测BCC、SCC与正常对照皮肤中Smad2、Smad3和Smad4mRNA的表达情况。结果：BCC和SCC皮损中Smad2、Smad3和Smad4mRNA的表达水平均显著低于正常人对照皮肤。结论：皮肤BCC和SCC中Smad2、Smad3和Smad4表达下调可直接或间接导致TGF-β抑制上皮细胞异常增殖和转化的作用受阻，从而有助于上述表皮肿瘤的形成和发展。     

基底细胞癌72例临床特征分析

目的：探讨皮肤基底细胞癌（ BCC）临床特征及可能诱因。方法：对72例患者的临床资料进行分析。结果：72例BCC中，平均发病年龄（68.03±12.91）岁，病程2个月～60年，平均（67.64±12.98）月。按皮损类型分型，结节溃疡型51例（70.83％），色素型5例（6.94％），浅表型9例（12.50％），硬斑型2例（2.78％），纤维上皮瘤型5例（6.94％）。头面部 BCC 共60例，占83.33％；肩部 BCC 6例（8.33％），均为农民或户外工人患者；颈部2例；后背、腋窝、腹部、踝部各1例。结论：BCC好发于头面部等曝光部位，也可以好发于职业相关性紫外线暴露部位。确诊后早期采用手术切除是主要而有效的治疗方法。     

组织蛋白酶D在皮肤鳞状细胞癌、基底细胞癌和脂溢性角化病的组织表达及其意义

目的：观察组织蛋白酶D（cathepsinD，CD）在皮肤鳞状细胞癌（SCC）、基底细胞癌（BCC）、脂溢性角化病（SK）的组织表达，分析其表达差异及其意义。方法：用免疫组化SP染色法检测CD在15例SCC、15例BCC、14例SK及10例正常对照皮肤组织中的表达。结果：CD在正常皮肤组织表达为阴性．在SK、BCC、SCC瘤组织中表达依次升高，在SCC、SK之间表达有显著性差异（P〈0．05）；CD在SK、BCC、SCC间质细胞表达阳性率分别为85．7％、66，7％、33．3％。结论：CD的表达水平可能与SCC侵袭和转移有关。     

Fas/FasL在基底细胞癌和鳞状细胞癌中的表达

目的:检测Fas/FasL在基底细胞癌(BCC)和鳞状细胞癌(SCC)中的表达.方法:采用SABC技术分别检测Fas/FasL在BCC、SCC及正常人对照皮肤中的表达.结果:Fas/FasL在BCC组不表达或弱表达,较正常人组无显著差异(P＞0.05);SCC组Fas和FasL的表达均高于对照皮肤(P＜0.05和＜0.01).Fasl染色主要集中于肿瘤细胞,弥漫染色,在肿瘤团块边缘表达更强;Fas在角珠处表达较强.结论:FasL在基底细胞癌不表达或弱表达,表明BCC侵袭扩散能力低,而在鳞状细胞癌中高表达可能与肿瘤的侵袭扩散能力高有关.     

HIF-1α和Glut-1在皮肤鳞状细胞癌和基底细胞癌中的表达

目的:检测缺氧诱导因子-1α(HIF-1α)、葡萄糖转运蛋白1(Glut-1)在皮肤鳞状细胞癌(SCC)、基底细胞癌(BCC)组织中的表达.方法:采用免疫组织化学方法检测74例SCC、71例BCC及30例正常皮肤组织中HIF-1α和Glut-1的表达.结果:SCC中HIF-1α和Glut-1蛋白阳性表达率分别为68.92%和82.43%.BCC中HIF-1α和Glut-1蛋白阳性表达率分别为61.97%和56.34%.均高于正常皮肤组织0%和6.67%(P<0.05).HIF-1α和Glut-1的表达与SCC和BCC患者的年龄、性别、分化程度无关,但与SCC淋巴结转移密切相关(P<0.05).结论:HIF-1α和Glut-1的过度表达可能与SCC和BCC的发生和转移有关.     

艾拉光动力治疗基底细胞癌15例疗效观察

目的观察光动力疗法治疗基底细胞癌(BCC)的临床疗效。方法 15例BCC患者予5-氨基酮戊酸(ALA)涂于皮损处3h~4h后行红光照射治疗约30min,能量密度范围在80~180J/cm2内,2周治疗一次,至少治疗4次。结果经4~10次治疗,15例BCC痊愈11例,部分反应3例,无效1例,有效率93.3%。结论对于年龄大、特殊部位、手术困难的老年BCC,PDT是可以考虑的有效替代治疗手段。     

5-氨基酮戊酸光动力治疗基底细胞癌疗效评价

目的:评价5-氨基酮戊酸光动力(ALA-PDT)治疗基底细胞癌的疗效及安全性.方法:回顾2016-2019年我院进行ALA-PDT治疗的17例基底细胞癌患者(浅表型14例,结节型3例)的临床资料.结果:14例浅表型基底细胞癌患者中13例患者皮损消退,仅留轻微色素沉着或色素减退,2例复发,1例于治疗后6个月后复发,1例于...     

Cutaneous lip tumours treated with Mohs micrographic surgery: clinical features and surgical outcome

BACKGROUND: The Australian Mohs micrographic surgery (MMS) database was initiated in 1993 by the Skin and Cancer Foundation Australia (SCFA) with the aim of collecting prospective data, and involved all Mohs surgeons in the country. OBJECTIVES: To present a large series of patients with cutaneous lip tumours treated with MMS in Australia between 1993 and 2002. METHODS: This prospective multicentre case series included all patients with cutaneous lip tumours who were monitored by the SCFA. The main outcome measures were patient demographics, reason for referral, duration of tumour, site, preoperative tumour size and postoperative defect size, recurrences prior to MMS, histological subtypes, perineural invasion and 5-year recurrence after MMS. RESULTS: There were 581 patients (66.1% women and 33.9% men, P < 0.0001) with a mean +/- SD age of 58 +/- 15 years. The upper lip was the most common site involved (81.1%). Basal cell carcinoma (BCC) was diagnosed in 82.3%, squamous cell carcinoma (SCC) in 16.5%, Bowen's disease (BD) in 0.7% and microcystic adnexal carcinoma (MAC) in 0.5% of cases. BCC was more common on the upper lip and in women, whereas SCC was more common on the lower lip and in men (P < 0.0001). Most upper lip tumours occurred in women (75.4%), whereas most lower lip tumours occurred in men (73.6%). SCC was associated with a larger tumour and postoperative defect size compared with the other tumours. The 5-year recurrence for BCC was 3.0%, and there were no cases of recurrence for SCC, BD or MAC. CONCLUSIONS: BCC was the most common cutaneous lip tumour managed by MMS, and was significantly more common on the upper lip and in women. The low 5-year recurrence rate emphasizes the importance of margin-controlled excision.     

Photodynamic therapy of eyelid basal cell carcinoma

Background  Photodynamic therapy (PDT; i.e. selective destroying of malignant cells by exposing them to red light after photosensitization) has been increasingly used for non-melanoma skin cancers. Due to excellent cosmetic and functional results, especially in difficult-to-treat areas, it may offer a comprehensive alternative to previous treatment modalities.
Objective  A series of six patient cases was used to evaluate the efficacy of PDT in the treatment of lower eyelid basal cell carcinoma (BCC).
Methods  Histological confirmation of BCC, a detailed demonstration of the technique with an illustrative series of cases and a review of related literature.
Results  Six patients with lower eyelid BCC were treated with two treatment sessions of PDT within a week. Five patients had a nodular type and one patient had a superficial type of BCC. The follow-up after treatment continued for 20–36 (mean 26.5) months. No recurrences were observed during the follow-up. All the patients were satisfied with the good results and tolerated the treatment well without any harm to the eyeball or surrounding skin.
Conclusion  PDT, although experimental in the eyelid area because of the small amount of data and the lack of a long-term follow-up, may be considered a promising comprehensive alternative when treating BCC in the eyelid area.

Conflicts of interest

None declared     

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

BACKGROUND: Imiquimod 5% cream has been investigated for non-surgical treatment of superficial and nodular basal cell carcinoma (BCC) tumours. OBJECTIVES: Two studies were conducted to examine the effect of occlusion at low dosing frequencies on the safety and efficacy of topical imiquimod 5% cream for the treatment of superficial and nodular BCC. PATIENTS AND METHODS: Both open-label studies were conducted in Europe. Patients diagnosed with BCC were enrolled into either the superficial (93 patients) or nodular (90 patients) study, depending on the histological confirmation of the patient's tumour subtype. Patients were randomized to one of four groups to apply imiquimod 5% cream 2 or 3 days per week either with or without occlusion. Six weeks following a 6-week treatment period, the entire target tumour area was excised and histologically examined for evidence of residual tumour. RESULTS: In both studies, the highest histologically complete response rate was seen in the 3 days per week with occlusion groups, with complete response rates of 87% and 65% for the superficial and nodular studies, respectively. Occlusion did not have a statistically significant effect on response rate at either dosing frequency. Response rates for superficial and nodular BCC tumours treated 3 days per week without occlusion were 76% and 50%, respectively. CONCLUSIONS: In the superficial study, the complete response rate of 87% in the 3 days per week with occlusion group was similar to that of daily and 5 days per week dosing without occlusion in a previous 12-week study and one study of daily dosing without occlusion for 6 weeks. All treatment groups had acceptable safety profiles in both studies. Occlusion did not have a statistically significant effect on efficacy for either superficial or nodular BCC tumours.